Introduction {#cpf12574-sec-0001}
============

Chronic bronchial inflammation of the respiratory mucosa can lead to bronchial hyperreactivity and airway obstruction. Clinicians often employ fractional exhaled nitric oxide (*F* ~ENO~) to evaluate bronchial eosinophilic inflammation (NICE, [2017](#cpf12574-bib-0015){ref-type="ref"}). *F* ~ENO~ values are flow‐dependent, and an expiratory flow rate of 50 ml s^−1^ mirrors the bronchial nitric oxide (NO) production and not the NO with peripheral origin (Tsoukias & George, [1998](#cpf12574-bib-0021){ref-type="ref"}; Högman *et al*., [2000](#cpf12574-bib-0005){ref-type="ref"}). For this reason, *F* ~ENO~ measurement is currently standardized at the expiratory flow rate of 50 ml s^−1^ (ATS/ERS, [2005](#cpf12574-bib-0001){ref-type="ref"}, Horváth *et al*., [2017](#cpf12574-bib-0006){ref-type="ref"}). Prior to the standardization, *F* ~ENO~ was acquired in Northern Europe with expiratory flow rates of 50‐300 ml s^−1^ (Högman *et al*., [1997](#cpf12574-bib-0004){ref-type="ref"}; Ekroos *et al*., [2002](#cpf12574-bib-0003){ref-type="ref"}; Rouhos *et al*., [2008](#cpf12574-bib-0018){ref-type="ref"}) and a previous guideline endorsed the use of flow rates between 167 and 250 ml s^−1^ (Kharitonov *et al*., [1997](#cpf12574-bib-0008){ref-type="ref"}). Many pioneers in *F* ~ENO~ investigation adopted a flow rate of 100 ml s^−1^ (Kharitonov & Barnes, [2001](#cpf12574-bib-0007){ref-type="ref"}). Unfortunately, data measured at different flow levels have been difficult to compare, since *F* ~ENO~ values are affected by the flow rate used and represent NO from anatomically different lung parts. Therefore, a conversion method to interpolate *F* ~ENO~ values to equivalent *F* ~ENO~ values at diverse flows was needed. Since the lowering effect of mouthwashes on *F* ~ENO~ values is well documented (Lassmann‐Klee *et al*., [2018a](#cpf12574-bib-0009){ref-type="ref"}, [2018b](#cpf12574-bib-0010){ref-type="ref"}), the conversion method should address also the mouthwashes. The aim of this study was to establish a method for converting *F* ~ENO~, measured at different expiratory flow levels, to the standard *F* ~ENO~ measured at 50 ml s^−1^ and validate this method. Further on, we aimed to determine the need of considering the mouthwashes in the conversion method.

Glossary {#cpf12574-sec-0002}
--------

*F* ~ENO~, Fractional exhaled nitric oxide

${\hat{F}}_{ENO}$, Estimated fractional exhaled nitric oxide

$\overset{˙}{V}$, Expiratory flow rate

NO, Nitric Oxide

Methods {#cpf12574-sec-0003}
=======

Data acquisition {#cpf12574-sec-0004}
----------------

We recruited 30 healthy or asthmatic adults as volunteers (henceforth referred as 'mixed adult population') to develop a conversion method. We have previously described this population (Lassmann‐Klee *et al*., [2018b](#cpf12574-bib-0010){ref-type="ref"}). The volunteers were adult patients (*n* = 9) or healthcare workers (*n* = 21). The patients invited were previously referred for *F* ~ENO~ assessment to the Laboratory of Clinical Physiology or to the Skin and Allergy Hospital at the Helsinki University Central Hospital area. The healthcare employees were included in the study without exclusions. The patients enrolled had respiratory symptoms or a chronic respiratory disease, including asthma (*n* = 4), eosinophilic bronchitis (*n* = 1), building‐related respiratory symptoms (*n* = 3) and Sjögren\'s syndrome (*n* = 1). Spirometric data (*n* = 25) were analysed, and none of the participants had actual bronchodilator reversibility (Pellegrino *et al*., [2005](#cpf12574-bib-0016){ref-type="ref"}).

*F* ~ENO~ measurements were performed at the Finnish Institute of Occupational Health and at the Skin and Allergy Hospital with CLD 88 sp chemiluminescence NO analysers and EXHALIZER®\'s D devices using SPIROWARE^®^ software (Eco Medics AG, Switzerland). The devices were calibrated in compliance with the producer\'s specifications: use of certified span gas (AGA Gas BV, Amsterdam, Netherlands) and a zero‐air filtering system (DENOX 88 unit). Additionally, a calibration syringe (Hans Rudolph Inc., USA) was used to calibrate the ultrasonic flow sensor. We complied with all advices from the ATS/ERS statement (ATS/ERS, [2005](#cpf12574-bib-0001){ref-type="ref"}).

We performed *F* ~ENO~ measurements in our mixed adult population (*n* = 30) from September 2016 until May 2017, and the tests for each volunteer were scheduled on 2 consecutive days. All the 30 volunteers followed a mouthwash protocol with tap water and carbonated water. Detailed description of the mouthwashes' protocol is available in our recent study (Lassmann‐Klee *et al*., [2018b](#cpf12574-bib-0010){ref-type="ref"}). Briefly, the *F* ~ENO~ measurements were performed after a mouthwash with 100 ml of tap water at each flow level. After 15 min, all measurements were repeated after a mouthwash with 100 ml of carbonated water at each flow level. The mouthwashes' effect, duration and chemical composition are well documented (Lassmann‐Klee *et al*., [2018a](#cpf12574-bib-0009){ref-type="ref"}, [2018b](#cpf12574-bib-0010){ref-type="ref"}).

Secondly, we selected 10 healthcare workers from the aforementioned volunteers to perform an additional measurement phase. The selection criterion was inclusion only of those employed at the Skin and Allergy Hospital. In the third appointments, the 10 healthcare workers performed the measurements without a mouthwash.

*F* ~ENO~ was acquired from all participants at the following multiple expiratory flow rates: 50, 30, 100 and 300 ml s^−1^. At least two measurements of *F* ~ENO~ were obtained at each flow level. The values were accepted, if its variation was less than 2 ppb.

Validation {#cpf12574-sec-0005}
----------

For validating our conversion method, 5 different datasets of previously published articles acquired at the Tampere University Hospital were available. They contained multiple‐flow data from 69 healthy adults (Lehtimäki *et al*., [2010a](#cpf12574-bib-0012){ref-type="ref"}, [2010b](#cpf12574-bib-0013){ref-type="ref"}), 66 healthy children (Sepponen *et al*., [2008](#cpf12574-bib-0019){ref-type="ref"}), 74 steroid‐naive adults with COPD (Lehtimäki *et al*., [2010a](#cpf12574-bib-0012){ref-type="ref"}), 40 steroid‐naive adults with asthma (Lehtimäki *et al*., [2001](#cpf12574-bib-0011){ref-type="ref"}) and 17 subjects with untreated alveolitis (Lehtimäki *et al*., [2001](#cpf12574-bib-0011){ref-type="ref"}). The validation process is explained in the statistical section.

This study followed the ethical principles of the declaration of Helsinki (World Medical Association Declaration of Helsinki, [2013](#cpf12574-bib-0022){ref-type="ref"}) and received approval from an ethical committee (99/13/03/00/15). All participants signed an informed consent.

Statistics {#cpf12574-sec-0006}
----------

### Modelling the conversion method {#cpf12574-sec-0007}

Analyses were performed using RSTUDIO® version 1·1·383 frontend to the R statistics language (R Core Team, [2018](#cpf12574-bib-0017){ref-type="ref"}). We agreed on a significance level of α = 0·05 as significant. We calculated the arithmetic mean from individual *F* ~ENO~ values obtained at each flow level. The mean values were plotted against the expiratory flow rate $\overset{˙}{V}$ in a double logarithmic scale, and we performed a non‐linear regression. We obtained a slope and intercept and analysed the regression line to develop our conversion model. To further refine the model, we acquired a non‐linear least squares estimation of the non‐linear model parameters. This model was used to estimate ${\hat{F}}_{ENO}$ values from *F* ~ENO~ values measured at different flow rates.

Validation {#cpf12574-sec-0008}
----------

To test the validity of our model, we converted *F* ~ENO~ values measured at 30, 100 and 300 ml s^−1^ to estimated ${\hat{F}}_{ENO}$ values for a standard flow rate of 50 ml s^−1^. Afterwards, we compared the estimated ${\hat{F}}_{ENO}$ values to the actual *F* ~ENO~ measured at 50 ml s^−1^. To assess the agreement between estimated ${\hat{F}}_{ENO}$ and measured *F* ~ENO~, we performed an analysis (see below) according to Bland & Altman ([2010](#cpf12574-bib-0002){ref-type="ref"}). Further on, the correlation coefficient rho was obtained with Spearman\'s formula to investigate linearity.

To validate our conversion model in different external populations, we compared the estimated ${\hat{F}}_{ENO}$ converted from 100 ml s^−1^ with *F* ~ENO~ measured at 50 or 40 ml s^−1^. For this external validation, a method described by Bland & Altman ([2010](#cpf12574-bib-0002){ref-type="ref"}) was employed. Accordingly, we obtained the individual differences of *F* ~ENO~, the mean of differences (bias) and the 1·96 standard deviations of the mean (95% limits of agreement).

Additionally, we performed a linear regression analysis (glm) between *F* ~ENO~ values measured at 50 ml s^−1^ after the tap water and carbonated water mouthwashes, to obtain a relation between the mouthwashes and to provide an additional equation to convert measurements with these two mouthwashes to the standard flow level (50 ml s^−1^).

When necessary, raw data were examined for outliers using the absolute deviation around the median (3 deviations as threshold). If cases were omitted, the conversion was repeated and the differences and level of agreements adjusted (Leys *et al*., [2013](#cpf12574-bib-0014){ref-type="ref"}).

Results {#cpf12574-sec-0009}
=======

Conversion model {#cpf12574-sec-0010}
----------------

We plotted the mean *F* ~ENO~ values against the expiratory flow rate $\overset{˙}{V}$ and performed a non‐linear regression. Acquiring non‐linear least squares parameter estimates resulted in a slope of −0·8416 SE(0·3192) for carbonated water, a slope of −0·84 SE(0·2989) for tap water and a slope of −0·83111 SE(0·05424) in the absence of a mouthwash. In the latter case, the equation model can be further defined as:

$${\hat{F}}_{ENO} = k \cdot {\overset{˙}{V}}^{- 0 \cdot 83111}$$

Plotting our model with Eq.  using measured *F* ~ENO~ and $\overset{˙}{V}$, as well as calculated values for *k*, resulted in Fig. [1](#cpf12574-fig-0001){ref-type="fig"}.

![*F*~ENO~ as a function of expiratory flow (without mouthwash), *n* = 10. Curve shows the equation${\hat{F}}_{ENO} = k \cdot {\overset{˙}{V}}^{- 0 \cdot 83111}$.](CPF-39-315-g001){#cpf12574-fig-0001}

The linear regression of *F* ~ENO~ at 50 ml s^−1^ after a tap water mouthwash in relation to carbonated water resulted in a slope coefficient of 1·055 ppb and intercept of 0·354 ppb (*P*\<0·001).

When employing the different estimating slopes for the ${\hat{F}}_{ENO}$ conversions with tap water and carbonated water mouthwashes, the mean estimated ${\hat{F}}_{ENO}$ for the carbonated water mouthwash was ca. −4·5% lower than the mean estimated ${\hat{F}}_{ENO}$ for tap water at all flow levels (unadjusted).

Validation results in mixed adult population {#cpf12574-sec-0011}
--------------------------------------------

Using Eq. [(1)](#cpf12574-disp-0001){ref-type="disp-formula"}, we calculated the values for ${\hat{F}}_{ENO}$ (flow level 50 ml s^−1^) interpolated from data obtained at 100 ml s^−1^. Applying the (Bland & Altman, [2010](#cpf12574-bib-0002){ref-type="ref"}) method resulted in mean (SD) differences between the estimated ${\hat{F}}_{ENO}$ (flow level 50 ml s^−1^) and the measured *F* ~ENO~ (flow level 50 ml s^−1^) of ‐0·45(2·44) ppb, upper 95% limit of agreement of 4·34 ppb and lower 95% limit of agreement of −5·23 ppb. The measured *F* ~ENO~ and the estimated ${\hat{F}}_{ENO}$ had a good correlation (Spearman\'s ρ = 0·87; *P*\<0·0001).

We also estimated ${\hat{F}}_{ENO}$ (50 ml s^−1^) from values measured at all flow levels and mouthwash settings. All differences with the (Bland & Altman, [2010](#cpf12574-bib-0002){ref-type="ref"}) method showed a good agreement, and the total unadjusted mean of the absolute deviation of ${\hat{F}}_{ENO}$ from *F* ~ENO~ was 0·72 ppb. All estimated values were highly correlated with corresponding measured values. Table [1](#cpf12574-tbl-0001){ref-type="table"} summarizes these results. Figure [2](#cpf12574-fig-0002){ref-type="fig"} exemplifies the unadjusted mean differences of ${\hat{F}}_{ENO}$ and *F* ~ENO~ after applying Eq. [(1)](#cpf12574-disp-0001){ref-type="disp-formula"} (conversion with carbonated water mouthwash from flow of 100 ml s^−1^). After adjusting measured *F* ~ENO~ by removing outliers and performing a new estimation, a better agreement was found between estimated ${\hat{F}}_{ENO}$ and measured *F* ~ENO~, and total mean of the absolute deviations of ${\hat{F}}_{ENO}$ from *F* ~ENO~ was 0·66 ppb. The adjusted results after controlling for outliers can be also found in Table [1](#cpf12574-tbl-0001){ref-type="table"}.

###### 

Bland--Altman statistics in our mixed healthy and asthmatic adult population (*n* = 30) and in healthcare workers (*n* = 10) with mean, bias[a](#cpf12574-note-0002){ref-type="fn"}, levels of agreement and standard deviation (SD) of the differences between estimated ${\hat{F}}_{ENO}$ from different flow levels and mouthwashes, and measured *F* ~ENO~ at 50 ml s^−1^ (tap water: 27·27 ppb; carbonated water: 25·51 ppb; no mouthwash: 22·05)

  Mean estimated ${\hat{F}}_{ENO}$ (ppb) at 50 ml s^−1^ from flow level and mouthwash   Bias[a](#cpf12574-note-0002){ref-type="fn"}           Adjusted values                                                       
  ------------------------------------------------------------------------------------- --------------------------------------------- ------- ----------------- ------- ------ ------- ------- ------ ------ ------ ---
  30 ml s^−1^; tap                                                                      25·24                                         −2·03   −11·17            7·10    4·66   −1·23   −5·44   3·0    2·15   0·96   3
  100 ml s^−1^; tap                                                                     26·99                                         −0·28   −7·42             6·86    3·64   −0·11   −3·67   3·44   1·81   0·98   3
  300 ml s^−1^; tap                                                                     26·27                                         −1·00   −19·02            17·01   9·19   0·74    −5·79   7·27   3·33   0·95   2
  30 ml s^−1^; carbonated                                                               24·23                                         −1·28   −4·92             2·36    1·86   −1·50   −4·90   1·90   1·73   0·99   3
  100 ml s^−1^; carbonated                                                              25·65                                         0·13    −4·28             4·55    2·25   −0·08   −3·32   3·16   1·65   0·99   4
  300 ml s^−1^; carbonated                                                              25·07                                         −0·44   −13·32            12·43   6·57   0·99    −4·69   6·67   2·90   0·95   4
  30 ml s^−1^; no mouthwash                                                             21·64                                         −0·41   −5·89             5·06    2·79   −0·41   −5·89   5·06   2·79   0·84   0
  100 ml s^−1^; no mouthwash                                                            21·60                                         −0·45   −5·23             4·34    2·44   −0·45   −5·23   4·34   2·44   0·87   0
  300 ml s^−1^; no mouthwash                                                            21·62                                         −0·43   −5·67             4·82    2·68   −0·43   −5·67   4·82   2·68   0·82   0

Raw data and adjusted values for outliers. Rho according to Spearman\'s test.

average of the differences between estimated ${\hat{F}}_{ENO}$ and measured *F* ~ENO~.

Number of observations excluded with the adjustment.

John Wiley & Sons, Ltd

![Bland--Altman plot with mean of measured *F*~ENO~ and estimated ${\hat{F}}_{ENO}$ from 100 ml s^−1^ in asthmatics (grey dots, *n* = 40) and our mixed adult population (black dots, *n* = 30), plotted against the differences in *F*~ENO~. In asthmatics: mean differences (grey dotted line), 1·96 standard deviations (grey dot‐slashed line). In mixed adult population: mean differences (black solid line), 1·96 standard deviation (black slashed line). In asthmatics *F*~ENO~ measured at 40 ml s^−1^. In mixed adult population *F*~ENO~ measured at 50 ml s^−1^ after carbonated water mouthwash.](CPF-39-315-g002){#cpf12574-fig-0002}

Validation results in external populations {#cpf12574-sec-0012}
------------------------------------------

With the same approach, we converted *F* ~ENO~ data obtained at 100 ml s^−1^ (Lauri Lehtimäki *et al*., [2001](#cpf12574-bib-0011){ref-type="ref"}; Sepponen *et al*., [2008](#cpf12574-bib-0019){ref-type="ref"}; Lehtimäki *et al*., [2010a](#cpf12574-bib-0012){ref-type="ref"}, [2010b](#cpf12574-bib-0013){ref-type="ref"}) to estimated ${\hat{F}}_{ENO}$ (flow level 50 or 40 ml s^−1^) without a mouthwash (Eq. ). The mean difference between estimated ${\hat{F}}_{ENO}$ and measured *F* ~ENO~ was lowest (0·27 ppb) in the healthy children group, followed by the healthy adult group (−0·44 ppb), as shown in Fig. [3](#cpf12574-fig-0003){ref-type="fig"}. The mean difference illustrated in Fig. [2](#cpf12574-fig-0002){ref-type="fig"} of steroid‐naive adults with asthma was −1·68 ppb. In Fig. [4](#cpf12574-fig-0004){ref-type="fig"}, the mean difference shown is −1·16 ppb in steroid‐naive adults with COPD, and 1·47 in the untreated alveolitis population. The healthy groups had narrow limits of agreement, in contrast to the groups with diseases. Table [2](#cpf12574-tbl-0002){ref-type="table"} synthesizes these results. Additionally, Fig. [5](#cpf12574-fig-0005){ref-type="fig"} demonstrates the distribution of the differences in all populations. Table [3](#cpf12574-tbl-0003){ref-type="table"} contains the correlation between the measured and estimated *F* ~ENO~ values and provides information concerning the linearity between the values.

![Bland--Altman plot with mean of *F*~ENO~ measured at 50 ml s^−1^ and estimated ${\hat{F}}_{ENO}$ from 100 ml s^−1^ in healthy children (grey dots, *n* = 66) and in healthy adults (black dots, *n* = 69), plotted against the differences in *F*~ENO~. In healthy children: mean differences (grey dotted line), 1·96 standard deviations (grey dot‐slashed line). In healthy adults: mean differences (black solid line), 1·96 standard deviation (black slashed line).](CPF-39-315-g003){#cpf12574-fig-0003}

![Bland--Altman plot with mean of measured *F*~ENO~ and estimated ${\hat{F}}_{ENO}$ from 100 ml s^−1^ in COPD patients (grey dots, *n* = 72) and patients with alveolitis (black dots, *n* = 17), plotted against the differences in *F*~ENO~. In COPD patients: mean differences (grey dotted line), 1·96 standard deviations (grey dot‐slashed line). In patients with alveolitis: mean differences (black solid line), 1·96 standard deviation (black slashed line). In patients with alveolitis *F*~ENO~ measured at 40 ml s^−1^. In COPD patients *F*~ENO~ measured at 50 ml s^−1^.](CPF-39-315-g004){#cpf12574-fig-0004}

###### 

Bland--Altman statistics with bias[a](#cpf12574-note-0004){ref-type="fn"}, levels of agreement and standard deviation (SD) of the differences between estimated ${\hat{F}}_{ENO}$ from 100 ml s^−1^ (Eq. 1) and measured *F* ~ENO~ at 50 or 40 ml s^−1^

  Population                           Bias[a](#cpf12574-note-0004){ref-type="fn"}   Level of agreement   SD      
  ------------------------------------ --------------------------------------------- -------------------- ------- ------
  Mixed healthy and asthmatic adults   −0·28                                         −7·42                6·86    3·64
  Healthy adults                       −0·44                                         −3·87                2·98    1·74
  Asthmatic                            −1·68                                         −11·36               7·99    4·94
  Healthy children                     0·27                                          −1·94                2·48    1·13
  COPD                                 −1·16                                         −11·46               9·13    5·25
  Alveolitis                           1·47                                          −8·28                11·22   4·98

average of the differences between estimated ${\hat{F}}_{ENO}$ and measured *F* ~ENO§.~

John Wiley & Sons, Ltd

![Density plot with mean differences between *F*~ENO~ measured at 50 or 40 ml s^−1^ and estimated ${\hat{F}}_{ENO}$ from 100 ml s^−1^, and the density of the individual mean differences in all study groups. \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](CPF-39-315-g005){#cpf12574-fig-0005}

###### 

Spearman\'s correlation between estimated ${\hat{F}}_{ENO}$ from 100 ml s^−1^ and measured *F* ~ENO~ at 50 ml s^−1^, with 95% CI and *P* values

  Population                           Correlation   95% CI   *P*    
  ------------------------------------ ------------- -------- ------ ---------
  Mixed healthy and asthmatic adults   0·99          0·98     0·99   \<0·001
  Healthy adults                       0·97          0·95     0·98   \<0·001
  Asthmatic                            0·99          0·98     0·99   \<0·001
  Healthy children                     0·97          0·95     0·98   \<0·001
  COPD                                 0·98          0·96     0·98   \<0·001
  Alveolitis                           0·87          0·68     0·95   \<0·001

John Wiley & Sons, Ltd

Discussion {#cpf12574-sec-0013}
==========

Conversion model {#cpf12574-sec-0014}
----------------

We found that using a non‐linear regression yielded a simple model to convert *F* ~ENO~ values measured at different flows to estimated ${\hat{F}}_{ENO}$ at 50 ml s^−1^. To prove the feasibility of the equation, we compared estimated ${\hat{F}}_{ENO}$ levels at the standard flow (50 ml s^−1^) from all flow levels (30, 100 and 300 ml s^−1^), with *F* ~ENO~ acquired at 50 ml s^−1^ and found a good mean agreement between the estimated and measured values. The limits of agreement between estimated ${\hat{F}}_{ENO}$ and *F* ~ENO~ were reasonable.

Validation {#cpf12574-sec-0015}
----------

Assessment of the conversion in external datasets, including data of a wide range of pulmonary diseases and multiple‐flow *F* ~ENO~ values, confirmed these previous findings. The conversion model developed showed the lowest deviation in *F* ~ENO~ conversions in healthy children, healthy adults and in our mixed asthmatic and healthy adult population. In the steroid‐naive asthmatic, alveolitis and COPD populations, the average differences in *F* ~ENO~ were moderate with moderate limits of agreement. In the population with COPD, some single individuals showed a considerable deviation.

We acknowledge the limitation of this conversion procedure, that is being only an approximation that may result in a considerable deviation between estimated and physiological values especially at extreme *F* ~ENO~ and/or flow levels, as observed in conversions from low flow (30 ml s^−1^) or high expiratory flow (300 ml s^−1^) levels. Nevertheless, this equation is useful when comparing the *F* ~ENO~ medians of large population data measured at different flow levels, being very reliable on the group level, although not on individual level. The conversion model developed suits best *F* ~ENO~ conversions in healthy adults, healthy children and in a mixed adult population, showing the lowest deviation. This novel conversion model mimics physiological expiratory NO values proportional to expiratory flows. Similar *F* ~ENO~ and expiratory flow curves were previously described by other researchers (Tsoukias & George, [1998](#cpf12574-bib-0021){ref-type="ref"}; Silkoff *et al*., [2000](#cpf12574-bib-0020){ref-type="ref"}), but this model uses a simplified approach in estimating ${\hat{F}}_{ENO}$ and makes no claim in predicting flow‐independent parameters.

Since the conversion model developed derives from healthy and asthmatic adults without alveolar diseases, the slope reflects only very low amounts of alveolar nitric oxide concentration (C~ANO~). We previously determined C~ANO~ in our mixed healthy and asthmatic group and all results were under 2·3 ppb (Lassmann‐Klee *et al*., [2018b](#cpf12574-bib-0010){ref-type="ref"}). Logically, the slope and the estimating equation would change, if switching the participants with subjects with high alveolar NO. The conversion method produces errors in those subjects in whom the relation between alveolar and bronchial NO production is very different from the group mean, as the slope between *F* ~ENO~ and $\overset{˙}{V}$ is very different in these subjects. Therefore, the model may result in erroneous estimates when applied to subjects with known high alveolar nitric oxide concentrations. Emphasis should be made, not to employ the model without discretion in this type of subjects. The elimination of outliers could represent a limitation of our study, although we did not observe drastic changes when comparing the bias between crude and adjusted data. This statistical adjustment merely narrowed the limits of agreement and served the purpose of demonstrating how the model estimates *F* ~ENO~ values stemming from adjusted datasets.

Further on, regression estimates were obtained for *F* ~ENO~ values between the mouthwashes, in order to facilitate an interpolation between *F* ~ENO~ values measured at 50 ml s^−1^ after carbonated, and tap water, and vice versa. Our estimating equation provides different slopes for both mouthwashes. The mean estimated ${\hat{F}}_{ENO}$ values were ca. 4% lower for the carbonated water mouthwash than the tap water mouthwash. This approximate difference between these mouthwashes was previously confirmed (Lassmann‐Klee *et al*., [2018a](#cpf12574-bib-0009){ref-type="ref"}, [2018b](#cpf12574-bib-0010){ref-type="ref"}). The conversion model succeeds also in considering the mouthwashes.

In conclusion, we developed an equation for converting *F* ~ENO~ values obtained with different flow levels to *F* ~ENO~ with standard flow (50 ml s^−1^), taking also into account the eventual mouthwash. We proposed a novel model to convert *F* ~ENO~ in healthy populations, as well in subjects with obstructive pulmonary diseases. We conclude that the model is reliable in converting *F* ~ENO~ in large epidemiological data and might be applied in small scale populations with pulmonary diseases, but not on individual level.
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